J
Jiwei Liu
Researcher at Dalian Medical University
Publications - 34
Citations - 5103
Jiwei Liu is an academic researcher from Dalian Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 8 publications receiving 4328 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of Rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M mutated NSCLC: a phase IIb study.
Yuankai Shi,Shiman Wu,K. Wang,Shundong Cang,Wen-xiu Yao,Yun Fan,Lin Wu,Mei-xia Huang,Xing-Ya Li,Yueyin Pan,Zhixiong Yang,Bo Zhu,Gongyan Chen,Jian Hua Shi,Meili Sun,Jian Fang,Lianjun Wang,Zhaohong Chen,Chunling Liu,Jingzhang Li,Jiwei Liu,Shenghua Sun,Yanqiu Zhao,Yanzhen Guo,Zili Meng,Zhefeng Liu,Zhigang Han,Hong Lu,Rui Ma,Sheng-Juan Hu,Guofang Zhao,Zheng Liu,Congying Xie,Diansheng Zhong,Huimin Zhao,Hui-Qing Yu,Longzhen Zhang,Minghong Bi,Shanyong Yi,Shuliang Guo,Tienan Yi,Wen Li,Ying Li,Yongqian Shu,Zhendong Chen,Zhongliang Guo,Michael Greco,Ting Wang,Hai-li Shen +48 more
TL;DR: Rezivertinib demonstrated promising efficacy and favorable safety profile for locally advanced or metastatic/recurrent NSCLC patients with EGFR T790M mutation.
Correction: A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor Initiating Cells and Overcomes Drug Resistance.
Feimeng Zheng,Zijie Long,Zhijie Hou,Yu Luo,Lingmin Xu,Jianglong Xia,Xiao Ju Lai,Jiwei Liu,Xi Wang,Muhammad Kamran,Min Yan,Shu Juan Shao,Eric Lam,Shaowu Wang,Gui Lu,Quentin Liu +15 more
Journal ArticleDOI
MO16-5 Gender survival disparities in the era of immune checkpoint inhibitors (ICI)
TL;DR: In this paper , gender may influence cancer patients' innate and adaptive immune responses, based on genetic and hormone factors, and there is much debate regarding the effectiveness of cancer immunotherapy in both male and female patients.
Journal ArticleDOI
Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study.
Yuankai Shi,Gongyan Chen,Xinkang Wang,Yunpeng Liu,Lin Wu,Yanrong Hao,Chunling Liu,Shu-yang Zhu,Xiaodong Zhang,Yuping Li,Jiwei Liu,Lejie Cao,Ying Chen,Huijun Zhao,Shucai Zhang,Aimin Zang,Jiuwei Cui,Jian Feng,Nong Yang,J. Hu +19 more
TL;DR: In this paper , the authors presented the positive benefit risk profile of first-line furmonertinib and further support this novel third generation EGFR-TKI as a new standard of first line treatment in EGFR mutation-positive NSCLC.
Journal ArticleDOI
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.
Sheng Yang,Shiman Wu,Yanqiu Zhao,Gongyan Chen,Bo Zhu,Xing-Ya Li,Kenneth K. Wang,Jian Hua Shi,Shundong Cang,Wen-xiu Yao,Yun Fan,Jian Fang,Liangming Zhang,Jianying Zhou,Linlin Wu,Rongsheng Zheng,Mei-xia Huang,Yueyin Pan,Zhixiong Yang,Meili Sun,Hui-Qing Yu,Donglin Wang,Jianan Huang,Lianjun Wang,Yongqian Shu,Zhaohong Chen,Chunling Liu,Jingzhang Li,Jiwei Liu,Shenghua Sun,Yanzhen Guo,Zili Meng,Zhefeng Liu,Zhigang Han,Gang Wu,Hong Lu,Rui Ma,Sheng-Juan Hu,Guofang Zhao,Longzhen Zhang,Zheng Liu,Congying Xie,Diansheng Zhong,Huimin Zhao,Minghong Bi,Shanyong Yi,Shuliang Guo,Tienan Yi,Wen Li,Ying Li,Zhendong Chen,Zhixiang Zhuang,Zhongliang Guo,Michael Greco,Ting Wang,Anqi Zhou,Yuankai Shi +56 more
TL;DR: Rezivertinib (BPI-7711) is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) which revealed the systematic and central nervous system (CNS) antitumor activities for EGFR T790M-mutated advanced NSCLC in previous clinical studies as mentioned in this paper .